Literature DB >> 7195414

A comparison of the efficacy of nalidixic acid and cephalexin in bacteriuric women and their effect on fecal and periurethral carriage of enterobacteriaceae.

J K Preiksaitis, L Thompson, G K Harding, T J Marrie, S Hoban, A R Ronald.   

Abstract

Eighty-one women were randomly selected for treatment with nalidixic acid (1 g four times a day) or cephalexin (500 mg four times a day) as therapy for 131 episodes of bacteriuria localized using the antibody-coated bacteria (ACB) test. Bladder infections were treated for three days and renal infections for 14 days. Rates of cure were not significantly different between treatment groups in each drug regimen. However, significantly more relapses occurred in the patients with ACB-positive infections treated for 14 days with cephalexin than in those treated for 14 days with nalidixic acid. More early reinfections occurred in the cephalexin-treated group after both three and 14 days of therapy. Resistance to nalidixic acid developed in the infecting bacteria in the urine during therapy with nalidixic acid in 3% of women after three days and in 16% of women after 14 days. Simultaneous resistance appeared in the urine, periurethral area, and fecal flora of these patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7195414     DOI: 10.1093/infdis/143.4.603

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  The quinolones and renal infection.

Authors:  A Ronald
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Oral antibiotic therapy for acute pyelonephritis: a methodologic review of the literature.

Authors:  A G Pinson; J T Philbrick; G H Lindbeck; J B Schorling
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

3.  Anti-microbial stewardship for urinary tract infection.

Authors:  C Sheehan; N Chew
Journal:  Ir J Med Sci       Date:  2005 Oct-Dec       Impact factor: 1.568

Review 4.  [Primary and secondary prevention of urinary tract infections].

Authors:  F M E Wagenlehner; W Vahlensieck; H W Bauer; W Weidner; K G Naber; H J Piechota
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

5.  Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.

Authors:  T Sandberg; G Englund; K Lincoln; L G Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

6.  The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community.

Authors:  R Cheung; C M Sullens; D Seal; J Dickins; P W Nicholson; A A Deshmukh; M J Denham; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

7.  Problem of antimicrobial resistance of fecal aerobic gram-negative bacilli in the elderly.

Authors:  T Leistevuo; P Toivonen; M Osterblad; M Kuistila; A Kahra; A Lehtonen; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

8.  Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.

Authors:  L K Selin; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Can J Infect Dis       Date:  1990

9.  [Recurrent urinary tract infection in women. Long-term antibiotic prophylaxis].

Authors:  M Ludwig; U Hoyme; W Weidner
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

10.  Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.

Authors:  D A Haase; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.